NIP-141, a multiple ion channel blocker, terminates aconitine-induced atrial fibrillation and prevents the rapid pacing-induced atrial effective refractory period shortening in dogs

Europace

Volumn 9, Issue 4, 2007, Pages 246-251

  Hashimoto, Norio ^a   Yamashita, Toru ^a   Fujikura, Naoki ^a   Tsuruzoe, Nobutomo ^a  

^a NISSAN CHEMICAL INDUSTRIES LTD   (Japan)

Author keywords

Antiarrhythmic agents; Atrial fibrillation; Ca2+ channel; Electrical remodelling; Na+ channel

Indexed keywords

4 CYCLOPROPYLAMINO 3,4 DIHYDRO 2,2 DIMETHYL 6 (4 METHOXYPHENYLACETHYLAMINO) 7 NITRO 2H 1 BENZOPYRAN 3 OL; ACONITINE; ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL L TYPE; DISOPYRAMIDE; NIP 141; PHENYTOIN; SODIUM CHANNEL; SOTALOL; UNCLASSIFIED DRUG; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG STRUCTURE; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM PACING; HEART CONDUCTION; MALE; NONHUMAN; PRIORITY JOURNAL; RADIOASSAY; RECEPTOR BINDING; REFRACTORY PERIOD; SINUS RHYTHM;

ANIMALS; ATRIAL FIBRILLATION; BENZOPYRANS; CARDIAC PACING, ARTIFICIAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEART CONDUCTION SYSTEM; ION CHANNELS; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 34047242225     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eum018     Document Type: Article

References (35)

1. Andrew M, Nelson BP. Atrial fibrillarion. Mount Sinai J of Med 2006; 73:482-92.
2. Lenz T, Hilleman D. Dofetilide, a new class III antiarrhythmic agent. Pharmacotherapy 2000;20:776-86.
3. Alliot E, Denjoy I. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patient with symptonic paroxysmal atrial fibrillation. Am. J. Cardoil 1996;77:66A-71.
4. Lenz T, Hillman D. Dofetilide. A new antiarrhythmic agent approved for convention and/or maintenance of atrial fibrillation/atrial flutter. Drugs Today (Barc) 1997;36:759-71.
5. Stroobandt R, Stiels B, Hoebreets R. Propafenone for conversion and prophylaxis of atrial fibrillation. Propafenone Atrial Fibrillation Trial Investigators. Am J Cardiol 1997;79:418-23.
6. Witchel HJ, Hancox JC. Familial and acquired Long QT syndrome and the cardiac rapid delayed rectifier potassium current. Clin Exp Pharmacol Physiol 2000;27:753-66.
7. Matsuda T, Takeda K, Ito M, Yamagishi R, Tamura M, Nakamura H et al. Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium. J Pharmacol Sci 2005;98:33-40.
8. Seki A, Hagiwara H, Kasanuki H. Effects of NIP-141 on K currents in human atrial myocytes. J Cardiovasc Pharmacol 2002;39:29-38.
9. Matsuda T, Masumiya H, Tanaka N, Yamashita T, Tsuruzoe N, Tanaka Y et al. Inhibition by a novel anti-arrhythmic agent, NIP-142, of cloned human cardiac K+ channel Kv1.5 current. Life Sci 2001;68:2017-24.
10. Matsuda T, Masumiya H, Saito T, Tanaka H, Shigenobu K, Yamashita T et al. NIP-142, a novel benzopyrane derivative: Electrophysiological study on the mechanism of bradycardiac effects. Jpn J Pharmacol 1998;79(Suppl. 1):178.
11. Nagasawa N, Fujiki A, Fujikura N, Matsuda T, Yamashita T, Inoue H. Effects of a novel class III antiarrhythmic agent, NIP-141, on canine atrial fibrillation and flutter. Circ J 2002;66:185-91.
12. Liu L, Nattle S. Different sympathetic and vagal effects on atrial fibrillation in dogs: Roles of refractoriness heterogeneity. Am J Physiol 1997; 273: H805-16.
13. Chen YJ, Chen SA, Tai CT, Wen ZC, Feng AN, Ding YA et al. Role of atrial electrophysiology and autonomic nervous system in patients with supraventricular tachycardia and paroxysmal atrial fibrillation. J Am Coll Cardiol 1998;32:732-8.
14. Lanari A, Lambertini A, Ravin A. Mechanism of experimental atrial flutter. Circ Res 1956;4:282-7.
15. Sugihura H, Chinushi M, Komura S, Hirano T, Aizawa Y. Heart rate variability is a useful parameter for evaluation of anticholinergic effect associated with inducibility of atrial fibrillation. Pacing Clin Electrophysiol 2005;28:1208-14.
16. Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P et al. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872. J Pharamacol Exp Ther 1996;276:637-46.
17. Thomsen MB, Verduyn SC, Stengi M, Beekman JD, de Pater G, van Opstal J et al. Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 2004;110: 2493-9.
18. Hashimoto K, Shibuya T, Imai S. Cardiovascular and respiratory effects of antiarrhythmic drugs on conscious beagles. Tohoku J Exp Med 1985; 145:359-67.
19. Yue L, Melnyk P, Gaspo R, Wang Z, Nattel S. Ionic remodeling underlying action potential changes in a canine model of atrial fibrillation. Circ Res 1997;84:776-84.
20. Attuel P, Childers R, Cauchemez B, Poveda J, Mujica J, Coumel P. Failure in the rate adaptation of the atrial refractory period: Its relationship to vulnerability. Int J Cardiol 1982;2:179-97.
21. Sawanobori T, Hirono Y, Hiraoka M. Aconitine-induced delayed afterdepolarization in the frog atrium and ventricle. Jpn J Pharmacol 1987; 37:59-79.
22. Levi AJ, Dallon GR, Hancox JC, Mitcheson JS, Issbemer J, Bates JA et al. Role of intracellular sodium overload in the genesis of cardiac arrhythmia. J Cardiovasc Electrophysiol 1997;8:700-21.
23. Friese J, Gleitz J, Gutser UT, Heubach JF, Matthiesen T, Wilffert B et al. Aconitum sp. alkaloids: The modulation of voltage-dependent Na+ channels, toxicity and antinociceptive properties. Eur J Pharmacol 1997; 337:165-74.
24. Lingamaneni R, Hemming HC Jr. Different interactions and antiepileptic drugs with neuronal Na+ channels, Ca2+ channels, and GABA(A) receptors. Br J Anaesth 2003;90:199-211.
25. Lu HR, Yang P, Remeysen P, Saels A, Dai DZ, De Clerck F. Ischemia/ reperfusion-induced arrhythmia in anaesthetized rats: A role of Na+ and Ca2+ influx. Eur J Pharmacol 1999;365:233-9.
26. Sugiyama A, Hashimoto K. Antiischemic effects of CP-060S, an inhibitor of pathologically modified sodium channel. J Cardiovasc Pharmacol 1999;33:70-7.
27. Ausma J, Wijffels M, Thone F, Wouters L, Allessie M, Bogers M. Structural changes of atrial myocardium, due to sustained atrial fibrillation in goat. Circulation 1997;96:3157-63.
28. Jayachandran JV, Winkle W, Sih HJ, Zipes DP, Hutchins GD, Oljin JE. Chronic atrial fibrillation from rapid atrial pacing is associated with reduced atrial blood flow: A positron emission tomography study. Circulation 1998;98(Suppl. 1):1-209.
29. Lee SH, Lin FY, Yu WC, Cheng JJ, Kuan P, Hung CR et al. Regional differences in the recovery course of tachycardia-induced changes of atrial electrophysiological properties. Circulation 1999;99: 1255-64.
30. Goette A, Honeycutt C, Langberg JJ. Electrical remodeling in atrial fibrillation. Time course and mechanism. Circulation 1996;94: 2968-74.
31. Daoud EG, Marcovitz P, Knight BP, Goyal R, Man KC, Strickberger SA et al. Short-term effects of atrial fibrillation on atrial contractile function in human. Circulation 1999;99:3024-7.
32. Ohashi N, Mitamura H, Tanimoto K, Fukuda Y, Kinebuchi O, Kimura Y et al. A comparison between calcium channel blocking drug with different potencies for T- and L-type channel in preventing atrial electrical remodeling. J Cardiovasc Pharmacol 2004;44:386-92.
33. Kojima J, Niwano S, Moriguchi M, Ikeda K, Inuo K, Saito J et al. Effects of pilsicainide on atrial electrophysiological properties in the canine rapid atrial stimulation model. Circ J 2003;67:340-6.
34. Lee SH, Lin FY, YU WC et al. Effects of verapamil on long-term tachycardia-induced atrial electrical remodeling. Circulation 2000;101: 200-6.
35. Fareh S, Benardeau A, Thibault B, Nattel S. The T-type Ca(2+) channel blacker mibefradil prevents the development of a substrate for atrial fibrillation. Circulation 1999;100:2191-7.